

# Dan V Iosifescu

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3598594/dan-v-iosifescu-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

185  
papers

10,632  
citations

50  
h-index

100  
g-index

206  
ext. papers

12,545  
ext. citations

5.5  
avg, IF

6.04  
L-index

#	Paper	IF	Citations
185	A mega-analysis of genome-wide association studies for major depressive disorder. <i>Molecular Psychiatry</i> , <b>2013</b> , 18, 497-511	15.1	853
184	Reduced caudate and nucleus accumbens response to rewards in unmedicated individuals with major depressive disorder. <i>American Journal of Psychiatry</i> , <b>2009</b> , 166, 702-10	11.9	804
183	Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. <i>American Journal of Psychiatry</i> , <b>2013</b> , 170, 1134-42	11.9	725
182	Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. <i>Biological Psychiatry</i> , <b>2013</b> , 74, 250-6	7.9	498
181	Reduced hedonic capacity in major depressive disorder: evidence from a probabilistic reward task. <i>Journal of Psychiatric Research</i> , <b>2008</b> , 43, 76-87	5.2	488
180	Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. <i>JAMA Psychiatry</i> , <b>2014</b> , 71, 681-8	14.5	337
179	A randomized controlled trial of intranasal ketamine in major depressive disorder. <i>Biological Psychiatry</i> , <b>2014</b> , 76, 970-6	7.9	277
178	Cognitive dysfunction in depression: neurocircuitry and new therapeutic strategies. <i>Neurobiology of Learning and Memory</i> , <b>2011</b> , 96, 553-63	3.1	222
177	Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. <i>Depression and Anxiety</i> , <b>2014</b> , 31, 335-43	8.4	220
176	QT interval and antidepressant use: a cross sectional study of electronic health records. <i>BMJ, The</i> , <b>2013</b> , 346, f288	5.9	205
175	Illness progression, recent stress, and morphometry of hippocampal subfields and medial prefrontal cortex in major depression. <i>Biological Psychiatry</i> , <b>2015</b> , 77, 285-294	7.9	201
174	Ketamine Treatment and Global Brain Connectivity in Major Depression. <i>Neuropsychopharmacology</i> , <b>2017</b> , 42, 1210-1219	8.7	179
173	A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. <i>Journal of Clinical Psychiatry</i> , <b>2006</b> , 67, 1754-9	4.6	149
172	Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in Major Depressive Disorder: results of the BRITE-MD study. <i>Psychiatry Research</i> , <b>2009</b> , 169, 124-31	9.9	140
171	Ketamine safety and tolerability in clinical trials for treatment-resistant depression. <i>Journal of Clinical Psychiatry</i> , <b>2015</b> , 76, 247-52	4.6	136
170	Brain bioenergetics and response to triiodothyronine augmentation in major depressive disorder. <i>Biological Psychiatry</i> , <b>2008</b> , 63, 1127-34	7.9	134
169	Euthymic patients with bipolar disorder show decreased reward learning in a probabilistic reward task. <i>Biological Psychiatry</i> , <b>2008</b> , 64, 162-8	7.9	131

168	Frontal EEG predictors of treatment outcome in major depressive disorder. <i>European Neuropsychopharmacology</i> , <b>2009</b> , 19, 772-7	1.2	128
167	Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). <i>Molecular Psychiatry</i> , <b>2020</b> , 25, 1592-1603	15.1	125
166	Cortical thickness abnormalities in cocaine addiction--a reflection of both drug use and a pre-existing disposition to drug abuse?. <i>Neuron</i> , <b>2008</b> , 60, 174-88	13.9	117
165	An automated registration algorithm for measuring MRI subcortical brain structures. <i>NeuroImage</i> , <b>1997</b> , 6, 13-25	7.9	113
164	Cholesterol in mood and anxiety disorders: review of the literature and new hypotheses. <i>European Neuropsychopharmacology</i> , <b>2004</b> , 14, 135-42	1.2	104
163	Microstructural abnormalities in subcortical reward circuitry of subjects with major depressive disorder. <i>PLoS ONE</i> , <b>2010</b> , 5, e13945	3.7	100
162	A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). <i>Psychotherapy and Psychosomatics</i> , <b>2012</b> , 81, 87-97	9.4	99
161	Reliability and validity of the Massachusetts general hospital cognitive and physical functioning questionnaire. <i>Psychotherapy and Psychosomatics</i> , <b>2009</b> , 78, 91-7	9.4	98
160	Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder. <i>Psychiatry Research</i> , <b>2009</b> , 169, 132-8	9.9	95
159	RESEARCH: Validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ). <i>CNS Neuroscience and Therapeutics</i> , <b>2010</b> , 16, 322-5	6.8	94
158	Electroencephalography-derived biomarkers of antidepressant response. <i>Harvard Review of Psychiatry</i> , <b>2011</b> , 19, 144-54	4.1	92
157	The impact of medical comorbidity on acute treatment in major depressive disorder. <i>American Journal of Psychiatry</i> , <b>2003</b> , 160, 2122-7	11.9	92
156	Efficacy and Safety of Low-field Synchronized Transcranial Magnetic Stimulation (sTMS) for Treatment of Major Depression. <i>Brain Stimulation</i> , <b>2015</b> , 8, 787-94	5.1	89
155	Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial. <i>Neuropsychopharmacology</i> , <b>2015</b> , 40, 1084-90	8.7	89
154	Reduced global functional connectivity of the medial prefrontal cortex in major depressive disorder. <i>Human Brain Mapping</i> , <b>2016</b> , 37, 3214-23	5.9	87
153	Review of transcranial photobiomodulation for major depressive disorder: targeting brain metabolism, inflammation, oxidative stress, and neurogenesis. <i>Neurophotonics</i> , <b>2016</b> , 3, 031404	3.9	86
152	Empirical testing of two models for staging antidepressant treatment resistance. <i>Journal of Clinical Psychopharmacology</i> , <b>2005</b> , 25, 336-41	1.7	79
151	Obesity among outpatients with major depressive disorder. <i>International Journal of Neuropsychopharmacology</i> , <b>2005</b> , 8, 59-63	5.8	74

150	Ketamine for treatment-resistant depression: recent developments and clinical applications. <i>Evidence-Based Mental Health</i> , <b>2016</b> , 19, 35-8	11.1	73
149	Stroke lesion in cortical neural circuits and post-stroke incidence of major depressive episode: a 4-month prospective study. <i>World Journal of Biological Psychiatry</i> , <b>2011</b> , 12, 539-48	3.8	68
148	In pursuit of neuroimaging biomarkers to guide treatment selection in major depressive disorder: a review of the literature. <i>Annals of the New York Academy of Sciences</i> , <b>2015</b> , 1344, 50-65	6.5	65
147	A randomized proof-of-mechanism trial applying the fast-fail approach to evaluating opioid antagonism as a treatment for anhedonia. <i>Nature Medicine</i> , <b>2020</b> , 26, 760-768	50.5	63
146	Near-Infrared Transcranial Radiation for Major Depressive Disorder: Proof of Concept Study. <i>Psychiatry Journal</i> , <b>2015</b> , 2015, 352979	2.4	59
145	Antidepressant response in patients with major depression exposed to NSAIDs: a pharmacovigilance study. <i>American Journal of Psychiatry</i> , <b>2012</b> , 169, 1065-72	11.9	59
144	Age-related changes in brain energetics and phospholipid metabolism. <i>NMR in Biomedicine</i> , <b>2010</b> , 23, 242-50	4.4	58
143	A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder. <i>Journal of Clinical Psychiatry</i> , <b>2013</b> , 74, e636-41	4.6	58
142	Corticotropin-Releasing Factor Receptor 1 Antagonism Is Ineffective for Women With Posttraumatic Stress Disorder. <i>Biological Psychiatry</i> , <b>2017</b> , 82, 866-874	7.9	57
141	Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response. <i>Psychopharmacology</i> , <b>2013</b> , 231, 481	4.7	57
140	The promise of ketamine for treatment-resistant depression: current evidence and future directions. <i>Annals of the New York Academy of Sciences</i> , <b>2015</b> , 1345, 47-58	6.5	56
139	Rare copy number variation in treatment-resistant major depressive disorder. <i>Biological Psychiatry</i> , <b>2014</b> , 76, 536-41	7.9	54
138	Lithium treatment moderate-dose use study (LiTMUS) for bipolar disorder: a randomized comparative effectiveness trial of optimized personalized treatment with and without lithium. <i>American Journal of Psychiatry</i> , <b>2013</b> , 170, 102-10	11.9	51
137	The detection of depression in medical setting: a study with PRIME-MD. <i>Journal of Affective Disorders</i> , <b>2006</b> , 91, 11-7	6.6	51
136	Brain white-matter hyperintensities and treatment outcome in major depressive disorder. <i>British Journal of Psychiatry</i> , <b>2006</b> , 188, 180-5	5.4	51
135	Mitochondrial modulators for bipolar disorder: a pathophysiologically informed paradigm for new drug development. <i>Australian and New Zealand Journal of Psychiatry</i> , <b>2013</b> , 47, 26-42	2.6	49
134	Cardiovascular risk factors may moderate pharmacological treatment effects in major depressive disorder. <i>Psychosomatic Medicine</i> , <b>2005</b> , 67, 703-6	3.7	48
133	Impact of medical comorbid disease on antidepressant treatment of major depressive disorder. <i>Current Psychiatry Reports</i> , <b>2004</b> , 6, 193-201	9.1	47

132	Tissue Type-Specific Bioenergetic Abnormalities in Adults with Major Depression. <i>Neuropsychopharmacology</i> , <b>2017</b> , 42, 876-885	8.7	45
131	The relation between mood, cognition and psychosocial functioning in psychiatric disorders. <i>European Neuropsychopharmacology</i> , <b>2012</b> , 22 Suppl 3, S499-504	1.2	44
130	Low-dose transdermal testosterone augmentation therapy improves depression severity in women. <i>CNS Spectrums</i> , <b>2009</b> , 14, 688-94	1.8	44
129	An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder. <i>Journal of Clinical Psychiatry</i> , <b>2005</b> , 66, 1038-42	4.6	43
128	A double-blind, placebo-controlled treatment trial of citalopram for major depressive disorder in older patients with heart failure: the relevance of the placebo effect and psychological symptoms. <i>Contemporary Clinical Trials</i> , <b>2009</b> , 30, 205-11	2.3	42
127	The combination of duloxetine and bupropion for treatment-resistant major depressive disorder. <i>Depression and Anxiety</i> , <b>2006</b> , 23, 178-81	8.4	42
126	Anhedonia in melancholic and non-melancholic depressive disorders. <i>Journal of Affective Disorders</i> , <b>2015</b> , 184, 81-8	6.6	41
125	Cognitive-emotional training as an intervention for major depressive disorder. <i>Depression and Anxiety</i> , <b>2014</b> , 31, 699-706	8.4	41
124	Parcellation of the human prefrontal cortex using MRI. <i>Psychiatry Research - Neuroimaging</i> , <b>1997</b> , 76, 29-40	2.9	41
123	Prevalence of incompletely penetrant Huntington@ disease alleles among individuals with major depressive disorder. <i>American Journal of Psychiatry</i> , <b>2010</b> , 167, 574-9	11.9	39
122	Transcranial Photobiomodulation for the Treatment of Major Depressive Disorder. The ELATED-2 Pilot Trial. <i>Photomedicine and Laser Surgery</i> , <b>2018</b> , 36, 634-646		39
121	A Randomized Dose-Ranging Study of Neuropeptide Y in Patients with Posttraumatic Stress Disorder. <i>International Journal of Neuropsychopharmacology</i> , <b>2018</b> , 21, 3-11	5.8	38
120	Comorbid medical illness and relapse of major depressive disorder in the continuation phase of treatment. <i>Psychosomatics</i> , <b>2004</b> , 45, 419-25	2.6	38
119	Tridimensional personality questionnaire factors in major depressive disorder: relationship to anxiety disorder comorbidity and age of onset. <i>Psychotherapy and Psychosomatics</i> , <b>2005</b> , 74, 173-8	9.4	37
118	Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. <i>Frontiers in Psychiatry</i> , <b>2020</b> , 11, 595584	5	37
117	Lithium treatment -- moderate dose use study (LiTMUS) for bipolar disorder: rationale and design. <i>Clinical Trials</i> , <b>2009</b> , 6, 637-48	2.2	36
116	Incident user cohort study of risk for gastrointestinal bleed and stroke in individuals with major depressive disorder treated with antidepressants. <i>BMJ Open</i> , <b>2012</b> , 2, e000544	3	36
115	Autonomic reactivity to induced emotion as potential predictor of response to antidepressant treatment. <i>Psychiatry Research</i> , <b>2007</b> , 151, 169-72	9.9	36

114	Serum cholesterol in treatment-resistant depression. <i>Neuropsychobiology</i> , <b>2003</b> , 47, 146-51	4	36
113	Galantamine-ER for cognitive dysfunction in bipolar disorder and correlation with hippocampal neuronal viability: a proof-of-concept study. <i>CNS Neuroscience and Therapeutics</i> , <b>2009</b> , 15, 309-19	6.8	35
112	Pilot investigation of isradipine in the treatment of bipolar depression motivated by genome-wide association. <i>Bipolar Disorders</i> , <b>2014</b> , 16, 199-203	3.8	34
111	The use of referenced-EEG (rEEG) in assisting medication selection for the treatment of depression. <i>Journal of Psychiatric Research</i> , <b>2011</b> , 45, 64-75	5.2	34
110	Limbic system white matter microstructure and long-term treatment outcome in major depressive disorder: a diffusion tensor imaging study using legacy data. <i>World Journal of Biological Psychiatry</i> , <b>2014</b> , 15, 122-34	3.8	33
109	Treating depression in the medically ill. <i>Psychiatric Clinics of North America</i> , <b>2007</b> , 30, 77-90	3.1	33
108	The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development. <i>Nature Reviews Drug Discovery</i> , <b>2018</b> , 18, 82-84	64.1	33
107	Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial. <i>Trials</i> , <b>2014</b> , 15, 240	2.8	31
106	Dextromethorphan/quinidine pharmacotherapy in patients with treatment resistant depression: A proof of concept clinical trial. <i>Journal of Affective Disorders</i> , <b>2017</b> , 218, 277-283	6.6	30
105	A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression. <i>Journal of Clinical Psychiatry</i> , <b>2011</b> , 72, 473-9	4.6	30
104	Using Electroencephalography for Treatment Guidance in Major Depressive Disorder. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , <b>2016</b> , 1, 411-422	3.4	30
103	A pilot study of minocycline for the treatment of bipolar depression: Effects on cortical glutathione and oxidative stress in vivo. <i>Journal of Affective Disorders</i> , <b>2018</b> , 230, 56-64	6.6	28
102	Diagnosis and treatment of major depressive disorder. <i>Neurologic Clinics</i> , <b>2011</b> , 29, 177-93, ix	4.5	26
101	Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part II). <i>Psychiatry Research - Neuroimaging</i> , <b>2005</b> , 140, 301-7	7.9	26
100	Effects of the KCNQ channel opener ezogabine on functional connectivity of the ventral striatum and clinical symptoms in patients with major depressive disorder. <i>Molecular Psychiatry</i> , <b>2020</b> , 25, 1323-1333	15.1	26
99	Baseline reward processing and ventrostriatal dopamine function are associated with pramipexole response in depression. <i>Brain</i> , <b>2020</b> , 143, 701-710	11.2	25
98	Cognition, functional capacity, and self-reported disability in women with posttraumatic stress disorder: examining the convergence of performance-based measures and self-reports. <i>Journal of Psychiatric Research</i> , <b>2014</b> , 57, 51-7	5.2	25
97	Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part I). <i>Psychiatry Research - Neuroimaging</i> , <b>2005</b> , 140, 291-9	2.9	25

96	Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis. <i>Journal of Clinical Psychiatry</i> , <b>2020</b> , 81,	4.6	25
95	Somatic symptoms as predictors of time to onset of response to fluoxetine in major depressive disorder. <i>Journal of Clinical Psychiatry</i> , <b>2004</b> , 65, 543-6	4.6	25
94	Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression. <i>Journal of Psychiatric Research</i> , <b>2019</b> , 110, 166-171	5.2	24
93	The influence of depressive symptoms on quality of life after stroke: a prospective study. <i>Journal of Stroke and Cerebrovascular Diseases</i> , <b>2015</b> , 24, 201-9	2.8	24
92	Major depressive disorder and comorbid cardiac disease: is there a depressive subtype with greater cardiovascular morbidity? Results from the STAR*D study. <i>Psychosomatics</i> , <b>2007</b> , 48, 418-25	2.6	24
91	Axis III disorders in treatment-resistant major depressive disorder. <i>Psychiatry Research</i> , <b>2003</b> , 118, 183-8	9.9	24
90	Quantitative electroencephalogram biomarkers for predicting likelihood and speed of achieving sustained remission in major depression: a report from the biomarkers for rapid identification of treatment effectiveness in major depression (BRITE-MD) trial. <i>Journal of Clinical Psychiatry</i> , <b>2013</b> , 74, 51-6	4.6	24
89	A clinical measure of suicidal ideation, suicidal behavior, and associated symptoms in bipolar disorder: Psychometric properties of the Concise Health Risk Tracking Self-Report (CHRT-SR). <i>Journal of Psychiatric Research</i> , <b>2015</b> , 71, 126-33	5.2	23
88	Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS). <i>Neuropsychopharmacology</i> , <b>2020</b> , 45, 1656-1663	8.7	23
87	31P-Magnetic Resonance Spectroscopy and Thyroid Hormones in Major Depressive Disorder: Toward a Bioenergetic Mechanism in Depression?. <i>Harvard Review of Psychiatry</i> , <b>2003</b> , 11, 51-63	4.1	23
86	31P-magnetic resonance spectroscopy and thyroid hormones in major depressive disorder: toward a bioenergetic mechanism in depression?. <i>Harvard Review of Psychiatry</i> , <b>2003</b> , 11, 51-63	4.1	22
85	Dopamine Release in Antidepressant-Naive Major Depressive Disorder: A Multimodal [C]-(+)-PHNO Positron Emission Tomography and Functional Magnetic Resonance Imaging Study. <i>Biological Psychiatry</i> , <b>2018</b> , 84, 563-573	7.9	22
84	Lithium continuation therapy following ketamine in patients with treatment resistant unipolar depression: a randomized controlled trial. <i>Neuropsychopharmacology</i> , <b>2019</b> , 44, 1812-1819	8.7	21
83	Major depressive disorder with anger attacks and subcortical MRI white matter hyperintensities. <i>Journal of Nervous and Mental Disease</i> , <b>2007</b> , 195, 175-8	1.8	21
82	Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression. <i>Depression and Anxiety</i> , <b>2019</b> , 36, 235-243	8.4	21
81	DNA methylation levels are associated with CRF receptor antagonist treatment outcome in women with post-traumatic stress disorder. <i>Clinical Epigenetics</i> , <b>2018</b> , 10, 136	7.7	21
80	Relationship between residual symptoms of depression and self-reported cognitive impairment. <i>CNS Spectrums</i> , <b>2010</b> , 15, 46-51	1.8	20
79	Major depressive disorder and inflammatory markers in elderly patients with heart failure. <i>Psychosomatics</i> , <b>2007</b> , 48, 319-24	2.6	20

78	Effect of medical comorbidity on response to fluoxetine augmentation or dose increase in outpatients with treatment-resistant depression. <i>Psychosomatics</i> , <b>2004</b> , 45, 224-9	2.6	20
77	The association of major depressive episode and personality traits in patients with fibromyalgia. <i>Clinics</i> , <b>2011</b> , 66, 973-8	2.3	18
76	White blood cell count correlates with mood symptom severity and specific mood symptoms in bipolar disorder. <i>Australian and New Zealand Journal of Psychiatry</i> , <b>2017</b> , 51, 355-365	2.6	17
75	Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD). <i>Brain Stimulation</i> , <b>2018</b> , 11, 75-84	5.1	14
74	Tissue-specific differences in brain phosphodiesterases in late-life major depression. <i>American Journal of Geriatric Psychiatry</i> , <b>2014</b> , 22, 499-509	6.5	14
73	The effect of personalized guideline-concordant treatment on quality of life and functional impairment in bipolar disorder. <i>Journal of Affective Disorders</i> , <b>2014</b> , 169, 144-8	6.6	14
72	Polypharmacy or medication washout: an old tool revisited. <i>Neuropsychiatric Disease and Treatment</i> , <b>2011</b> , 7, 639-48	3.1	14
71	Prevalence of MTHFR C677T and MS A2756G polymorphisms in major depressive disorder, and their impact on response to fluoxetine treatment. <i>CNS Spectrums</i> , <b>2012</b> , 17, 76-86	1.8	14
70	Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression. <i>Journal of Affective Disorders</i> , <b>2020</b> , 260, 131-139	6.6	14
69	Neuropeptide Y in PTSD, MDD, and chronic stress: A systematic review and meta-analysis. <i>Journal of Neuroscience Research</i> , <b>2020</b> , 98, 950-963	4.4	14
68	Reported Side Effects, Weight and Blood Pressure, After Repeated Sessions of Transcranial Photobiomodulation. <i>Photobiomodulation, Photomedicine, and Laser Surgery</i> , <b>2019</b> , 37, 651-656	2.8	12
67	Biomarkers in major depressive disorder: the role of mass spectrometry. <i>Advances in Experimental Medicine and Biology</i> , <b>2014</b> , 806, 545-60	3.6	12
66	Feasibility of studying brain morphology in major depressive disorder with structural magnetic resonance imaging and clinical data from the electronic medical record: a pilot study. <i>Psychiatry Research - Neuroimaging</i> , <b>2013</b> , 211, 202-13	2.9	12
65	Recognition of depressive symptoms by physicians. <i>Clinics</i> , <b>2009</b> , 64, 629-35	2.3	12
64	Effects of transcranial photobiomodulation with near-infrared light on sexual dysfunction. <i>Lasers in Surgery and Medicine</i> , <b>2019</b> , 51, 127-135	3.6	12
63	Psychophysiological treatment outcomes: Corticotropin-releasing factor type 1 receptor antagonist increases inhibition of fear-potentiated startle in PTSD patients. <i>Psychophysiology</i> , <b>2020</b> , 57, e13356	4.1	12
62	Major depressive disorder with anger attacks and cardiovascular risk factors. <i>International Journal of Psychiatry in Medicine</i> , <b>2007</b> , 37, 99-111	1	11
61	Ketamine and ECT: better alone than together?. <i>Lancet Psychiatry</i> , <b>2017</b> , 4, 348-349	23.3	10

60	The Medication Recommendation Tracking Form: a novel tool for tracking changes in prescribed medication, clinical decision making, and use in comparative effectiveness research. <i>Journal of Psychiatric Research</i> , <b>2013</b> , 47, 1686-93	5.2	10
59	Importance of retardation and fatigue/interest domains for the diagnosis of major depressive episode after stroke: a four months prospective study. <i>Revista Brasileira De Psiquiatria</i> , <b>2009</b> , 31, 202-7	2.6	10
58	Serum cholesterol in the continuation phase of pharmacotherapy with fluoxetine in remitted major depressive disorder. <i>Journal of Clinical Psychopharmacology</i> , <b>2004</b> , 24, 467-9	1.7	10
57	T3 blood levels and treatment outcome in depression. <i>International Journal of Psychiatry in Medicine</i> , <b>2001</b> , 31, 367-73	1	10
56	The use of the Psychiatric Electroencephalography Evaluation Registry (PEER) to personalize pharmacotherapy. <i>Neuropsychiatric Disease and Treatment</i> , <b>2016</b> , 12, 2131-42	3.1	10
55	Plasma Neuronal and Glial Markers and Anterior Cingulate Metabolite Levels in Major Depressive Disorder: A Pilot Study. <i>Neuropsychobiology</i> , <b>2020</b> , 79, 214-221	4	9
54	The association of post-stroke anhedonia with salivary cortisol levels and stroke lesion in hippocampal/parahippocampal region. <i>Neuropsychiatric Disease and Treatment</i> , <b>2015</b> , 11, 233-42	3.1	9
53	Transcranial Photobiomodulation For The Management Of Depression: Current Perspectives. <i>Neuropsychiatric Disease and Treatment</i> , <b>2019</b> , 15, 3255-3272	3.1	9
52	Combined effects of genotype and childhood adversity shape variability of DNA methylation across age. <i>Translational Psychiatry</i> , <b>2021</b> , 11, 88	8.6	9
51	The Influence of Depression on the Psychometric Properties of the Maslach Burnout Inventory-Human Services Survey: A Cross-Sectional Study With Nursing Assistants. <i>Frontiers in Psychiatry</i> , <b>2018</b> , 9, 695	5	9
50	Methods to limit attrition in longitudinal comparative effectiveness trials: lessons from the Lithium Treatment - Moderate dose Use Study (LiTMUS) for bipolar disorder. <i>Clinical Trials</i> , <b>2012</b> , 9, 94-101	2.2	8
49	Clinically relevant and simple immune system measure is related to symptom burden in bipolar disorder. <i>Acta Neuropsychiatrica</i> , <b>2018</b> , 30, 297-305	3.9	8
48	An exploratory study of responses to low-dose lithium in African Americans and Hispanics. <i>Journal of Affective Disorders</i> , <b>2015</b> , 178, 224-8	6.6	7
47	The buildup of an urge in obsessive-compulsive disorder: Behavioral and neuroimaging correlates. <i>Human Brain Mapping</i> , <b>2020</b> , 41, 1611-1625	5.9	7
46	A randomized, double-blind, placebo-controlled, dose-ranging study of lisdexamfetamine dimesylate augmentation for major depressive disorder in adults with inadequate response to antidepressant therapy. <i>Journal of Psychopharmacology</i> , <b>2017</b> , 31, 1190-1203	4.6	7
45	Placebo Effects Across Self-Report, Clinician Rating, and Objective Performance Tasks Among Women With Post-Traumatic Stress Disorder: Investigation of Placebo Response in a Pharmacological Treatment Study of Post-Traumatic Stress Disorder. <i>Journal of Clinical Psychopharmacology</i> , <b>2017</b> , 37, 200-207	1.7	6
44	Retrospective chart review of a referenced EEG database in assisting medication selection for treatment of depression in patients with eating disorders. <i>Neuropsychiatric Disease and Treatment</i> , <b>2011</b> , 7, 529-41	3.1	6
43	Biological predictors of treatment response in affective illness. <i>Psychiatric Clinics of North America</i> , <b>2003</b> , 26, 323-44, vii	3.1	6

42	Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial. <i>American Journal of Psychiatry</i> , <b>2021</b> , 178, 437-446	11.9	6
41	Effect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial.. <i>American Journal of Psychiatry</i> , <b>2022</b> , appiajp21080800	11.9	6
40	Clinical characteristics of depressed patients with comorbid diabetes mellitus. <i>International Clinical Psychopharmacology</i> , <b>2006</b> , 21, 43-7	2.2	5
39	Maintaining the initial clinical response after ketamine in bipolar and unipolar depression: an important next-step challenge. <i>Journal of Clinical Psychiatry</i> , <b>2015</b> , 76, 738-40	4.6	5
38	A randomized, controlled pilot trial of the Emotional Faces Memory Task: a digital therapeutic for depression. <i>Npj Digital Medicine</i> , <b>2018</b> , 1,	15.7	5
37	A novel application of the Intent to Attend assessment to reduce bias due to missing data in a randomized controlled clinical trial. <i>Clinical Trials</i> , <b>2014</b> , 11, 494-502	2.2	4
36	The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study. <i>European Neuropsychopharmacology</i> , <b>2021</b> , 49, 122-132	1.2	4
35	Executive function and depressive symptoms of retardation in nonelderly stroke patients. <i>Journal of Clinical and Experimental Neuropsychology</i> , <b>2014</b> , 36, 636-47	2.1	3
34	Use of treatment services in a comparative effectiveness study of bipolar disorder. <i>Psychiatric Services</i> , <b>2013</b> , 64, 1119-26	3.3	3
33	Familial severe psychiatric history in bipolar disorder and correlation with disease severity and treatment response. <i>Journal of Affective Disorders</i> , <b>2020</b> , 273, 131-137	6.6	3
32	Adjunctive antidepressant treatment among 763 outpatients with bipolar disorder: Findings from the Bipolar CHOICE and LiTMUS trials. <i>Depression and Anxiety</i> , <b>2021</b> , 38, 114-123	8.4	3
31	Temporal Stability of Cognitive Functioning and Functional Capacity in Women with Posttraumatic Stress Disorder. <i>Archives of Clinical Neuropsychology</i> , <b>2019</b> , 34, 539-547	2.7	2
30	Protein Biomarkers in Major Depressive Disorder: An Update. <i>Advances in Experimental Medicine and Biology</i> , <b>2019</b> , 1140, 585-600	3.6	2
29	GABA-A receptor modulators: can they offer any improvement over benzodiazepines in the treatment of anxiety disorders?. <i>CNS Neuroscience and Therapeutics</i> , <b>2010</b> , 16, 61-2	6.8	2
28	Correlation between S100B and severity of depression in MDD: A meta-analysis. <i>World Journal of Biological Psychiatry</i> , <b>2021</b> , 1-11	3.8	2
27	Dimensions of interoception in obsessive-compulsive disorder. <i>Journal of Obsessive-Compulsive and Related Disorders</i> , <b>2020</b> , 27, 100584-100584	1.7	2
26	Influences on childhood depressive symptoms: The effects of trauma and distress tolerance across age and sex groups. <i>Journal of Affective Disorders</i> , <b>2021</b> , 283, 373-376	6.6	2
25	Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. <i>Focus (American Psychiatric Publishing)</i> , <b>2021</b> , 19, 222-242	1.1	2

24	The influence of depression on personality traits in patients with fibromyalgia: a case-control study. <i>Clinical and Experimental Rheumatology</i> , <b>2017</b> , 35 Suppl 105, 13-19	2.2	2
23	Correlation between white blood cell count and mood-stabilising treatment response in two bipolar disorder trials. <i>Acta Neuropsychiatrica</i> , <b>2019</b> , 31, 230-234	3.9	1
22	Measuring severe adverse events and medication selection using a "PEER Report" for nonpsychotic patients: a retrospective chart review. <i>Neuropsychiatric Disease and Treatment</i> , <b>2012</b> , 8, 277-84	3.1	1
21	The Impact of Medical Comorbidity on Acute Treatment in Major Depressive Disorder. <i>Focus (American Psychiatric Publishing)</i> , <b>2005</b> , 3, 69-75	1.1	1
20	Relationships between interoceptive sensibility and resting-state functional connectivity of the insula in obsessive-compulsive disorder.. <i>Cerebral Cortex</i> , <b>2022</b> ,	5.1	1
19	Neural Predictors of the Antidepressant Placebo Response. <i>Pharmaceuticals</i> , <b>2019</b> , 12,	5.2	1
18	Initial Evidence for Brain Plasticity Following a Digital Therapeutic Intervention for Depression. <i>Chronic Stress</i> , <b>2019</b> , 3, 2470547019877880	3	0
17	A systematic review and network meta-analysis of carbon dioxide provocation in psychiatric disorders. <i>Journal of Psychiatric Research</i> , <b>2021</b> , 143, 508-515	5.2	0
16	Are Electroencephalogram-Derived Predictors of Antidepressant Efficacy Closer to Clinical Usefulness?. <i>JAMA Network Open</i> , <b>2020</b> , 3, e207133	10.4	0
15	Imbalance between default mode and sensorimotor connectivity is associated with perseverative thinking in obsessive-compulsive disorder.. <i>Translational Psychiatry</i> , <b>2022</b> , 12, 19	8.6	0
14	Differential reinforcement learning responses to positive and negative information in unmedicated individuals with depression. <i>European Neuropsychopharmacology</i> , <b>2021</b> , 53, 89-100	1.2	0
13	Lithium plus antipsychotics or anticonvulsants for bipolar disorder: Comparing clinical response and metabolic changes.. <i>Australian and New Zealand Journal of Psychiatry</i> , <b>2022</b> , 48674221077619	2.6	0
12	Lithium Treatment Moderate-Dose Use Study (LiTMUS) for Bipolar Disorder: A Randomized Comparative Effectiveness Trial of Optimized Personalized Treatment With and Without Lithium. <i>Focus (American Psychiatric Publishing)</i> , <b>2015</b> , 13, 94-101	1.1	
11	Glutamate Modulators in Major Depressive Disorder <b>2020</b> , 169-174		
10	Clinical applications of neuroimaging for treating depressive disorders. <i>Psychiatry</i> , <b>2009</b> , 6, 49-51		
9	Affective and somatic symptom clusters in depression and their relationship to treatment outcomes in the STAR*D sample.. <i>Journal of Affective Disorders</i> , <b>2021</b> , 300, 469-469	6.6	
8	Neuroimaging and Electrophysiology Studies in Major Depressive Disorder. <i>Medical Psychiatry</i> , <b>2009</b> , 150-165		
7	Depression: Diagnosis and Treatment <b>2013</b> , 949-961		

- 6 Using Placebo Response to Pain as a Predictor of Placebo Response in Mood Disorders. *Current Behavioral Neuroscience Reports*, **2016**, 3, 360-367 1.7
- 5 Chapter 40 Transcranial Near-Infrared Light for Major Depressive Disorder **2016**, 809-824
- 4 Depressive Disorders **2016**, 57-73
- 3 Bipolar Disorders **2016**, 74-87
- 2 A 12-Month Open-Label Extension Study of the Safety and Tolerability of Lisdexamfetamine Dimesylate for Major Depressive Disorder in Adults. *Journal of Clinical Psychopharmacology*, **2018**, 38, 336-343 1.7
- 1 Response and remission rates during 24 weeks of mood-stabilizing treatment for bipolar depression depending on early non-response. *Psychiatry Research*, **2021**, 305, 114194 9.9